Stephens Inc. AR Boosts Stake in Enovis Corporation $ENOV

Stephens Inc. AR raised its holdings in shares of Enovis Corporation (NYSE:ENOV) by 2.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 91,864 shares of the company’s stock after buying an additional 2,612 shares during the quarter. Stephens Inc. AR owned about 0.16% of Enovis worth $2,881,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Enovis by 11.3% in the 1st quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company’s stock valued at $233,356,000 after acquiring an additional 621,069 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in shares of Enovis by 191.5% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 810,771 shares of the company’s stock valued at $26,772,000 after acquiring an additional 532,648 shares during the last quarter. Invenomic Capital Management LP lifted its stake in shares of Enovis by 199.6% in the 1st quarter. Invenomic Capital Management LP now owns 449,777 shares of the company’s stock valued at $17,186,000 after acquiring an additional 299,658 shares during the last quarter. DAVENPORT & Co LLC lifted its stake in shares of Enovis by 10.4% in the 1st quarter. DAVENPORT & Co LLC now owns 3,071,985 shares of the company’s stock valued at $116,489,000 after acquiring an additional 289,644 shares during the last quarter. Finally, Paradigm Capital Management Inc. NY lifted its stake in shares of Enovis by 47.5% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 786,400 shares of the company’s stock valued at $30,048,000 after acquiring an additional 253,200 shares during the last quarter. Institutional investors own 98.45% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on ENOV shares. UBS Group cut their price target on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Wells Fargo & Company cut their price target on Enovis from $48.00 to $41.00 and set an “overweight” rating on the stock in a research note on Friday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Enovis in a research note on Wednesday, October 8th. Evercore ISI cut their target price on Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research note on Tuesday, July 8th. Finally, Needham & Company LLC cut their target price on Enovis from $57.00 to $49.00 and set a “buy” rating on the stock in a research note on Thursday, August 7th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $51.00.

Enovis Price Performance

Shares of Enovis stock opened at $32.77 on Thursday. Enovis Corporation has a one year low of $25.47 and a one year high of $49.83. The stock’s fifty day moving average is $31.09 and its 200 day moving average is $31.54. The stock has a market cap of $1.87 billion, a P/E ratio of -2.30 and a beta of 1.69. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.15 and a current ratio of 2.25.

Enovis (NYSE:ENOV) last announced its earnings results on Monday, January 8th. The company reported $0.59 EPS for the quarter. Enovis had a positive return on equity of 6.78% and a negative net margin of 37.80%.The company had revenue of $383.81 million for the quarter. Sell-side analysts anticipate that Enovis Corporation will post 2.79 earnings per share for the current year.

Insider Buying and Selling

In other Enovis news, SVP Bradley J. Tandy purchased 3,200 shares of Enovis stock in a transaction dated Friday, August 22nd. The shares were acquired at an average cost of $31.41 per share, with a total value of $100,512.00. Following the completion of the transaction, the senior vice president owned 43,515 shares in the company, valued at approximately $1,366,806.15. This trade represents a 7.94% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Damien Mcdonald purchased 6,457 shares of Enovis stock in a transaction dated Thursday, September 11th. The shares were acquired at an average cost of $30.97 per share, for a total transaction of $199,973.29. Following the completion of the transaction, the chief executive officer owned 102,753 shares of the company’s stock, valued at approximately $3,182,260.41. This represents a 6.71% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 12,157 shares of company stock valued at $374,760 over the last 90 days. Corporate insiders own 2.70% of the company’s stock.

Enovis Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.